Regeneron, Bayer commence Phase 3 trial of Eylea Injection
Eylea, also known VEGF Trap-Eye, is a recombinant fusion protein, consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of
Evogene and ELEO have entered a scientific collaboration aimed at discovering and developing new oral small-molecule inhibitors targeting the Proprotein convertase subtilisin/kexin type 9 (PCSK9) pathway for hyperlipidemia and cardiovascular diseases.
The institute will transform basic discoveries into new drugs and complementary diagnostics for cancer patients besides improving translational and clinical research, newswise.com reported. MD Anderson president Ronald DePinho